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Introduction
Oxygen therapy is generally provided via nasal cannula,
non-rebreathing masks and masks with reservoir bags.
These devices have various limitations.
Despite showing clear benefits in certain conditions,
non-invasive positive pressure ventilation (NIPPV) limits
mobilization, restricts communication and oral nutrition
and is poorly tolerated by some patients due to discomfort.
High-flow nasal cannula oxygen (HFNC) delivers a high
flow of heated and humidified oxygen through nasal
prongs. It generate positive airway pressure, reduces
respiratory dead space, airway resistance, and less frequent
interruption of therapy.
Objectives
The primary aim of this study was to compare HFNC and
NIPPV efficacy to prevent endotracheal intubation in
patients with acute hypoxemic respiratory failure. Secon-
darily to access comfort, ventilatory and oxygenation
parameters.
Methods
We included all adult patients admitted to a 45-bed medi-
cal surgical ICU in the period from December 2013 to
March 2015, with acute hypoxemic respiratory failure
defined as SpO2 < 95% while receiving oxygen through a
facemask at an estimated FIO2= 50%. The study was
approved by the Ethics Committee of Sao Domingos
Hospital.
HFNC oxygen was delivered via a high flow delivery
system (Optiflow; Fisher &Paykel, Aukland New Zeland)
and an air-oxygen blender that delivers a gas flow of up
to 60 liters/min to a heated humidifier (Fisher&Paykel
MR 850).
NIPPV was delivered with a full-face mask (Performax,
Philips Respironics), connected to an ICU ventilator with
a NIV mode Patients were ventilated in the mode pressure
support.
Comfort was evaluated through modified Borg scale at
baseline and at the end of therapy. Respiratory rate and
SpO2/FIO2 were measured at baseline and after 6, 12 and
24 hours of support.
Clinical stabilization was defined as a SpO2 > 94% and
respiratory rate < 28 rpm with a low flow oxygen nasal
catheter or Venturi ≤ 0.40. Successful treatment was
defined by avoidance of intubation.
Results
Thirty-five patients were submitted to randomization. Five
were excluded from analysis. Thus, 30 patients were ana-
lyzed, 14 in HFNC group and 16 in NIPPV group. Both
groups were comparable regarding to age, gender and
APACHE IV score (Table 1). Twelve patients were
intubated due to failure of therapy (6 in each group).
Three interruptions of therapy were motivated by patient
intolerance (2 NIPPV and 1 HFNC). Modified Borg scale
improved substantially in both groups (Figure 1 Panel A).
Improvement of respiratory rate and PbO2/FIO2 also
were expressive in both groups after beginning therapy
(Figure 1 Panel B and C).
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Conclusions
We found no significant difference in the necessity of
endotracheal intubation and invasive ventilation in
patients with hypoxemic respiratory failure managed
with HFNC compared to NIPPV.
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Age, y, mean (SD) 61,4 (13.7) 72.3 (19.0) 0.08 Outcome Intubation 9 (64.2) 9 (56.2) 0.72
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